id: sig-20260710-vms-nonhormone-recommended
site_id: vasomotor-symptoms
site_hint: "vasomotor symptoms — symptom"
attribute: guideline_recommendation
value: "Recommended for vasomotor symptoms at Level I evidence (good and consistent scientific evidence): cognitive-behavioral therapy, clinical hypnosis, SSRIs/SNRIs, gabapentin, and fezolinetant (a neurokinin 3 receptor antagonist, first-in-class FDA-approved). Oxybutynin recommended at Levels I-II; weight loss and stellate ganglion block at Levels II-III."
source_url: https://pubmed.ncbi.nlm.nih.gov/37252752/
source_title: "The Menopause Society — 2023 Nonhormone Therapy Position Statement (Menopause, 2023; PMID 37252752)"
publisher: The Menopause Society (Menopause journal)
source_date: "2023"
observed_date: "2026-07-10"
collected_by: gn_info_scout/1.0.0
confidence: high